Sputnik V, which was developed by Gamaleya Institute in Moscow, was licensed for use in Russian Federation in August.
The race against covid-19 does not stop showing progress in the field of medicine, since in recent weeks countries such as the United States and Russian Federation have presented their vaccines to eradicate and prevent the spread of the virus.
According to The Lancet, there are now 42 vaccines for COVID-19 in clinical trials. However, no vaccine has yet been licensed."In China, there are four vaccines that are in the final phase of clinical trials, with some of them showing promising results, such as Sinovac, according to the scientific journal The Lancet", continues the journalist. But it is going to be the first time that the government has publicly made a vaccine like this available for the citizens. More on Covid-19Dr Reddy's co-chairman and managing director G V Prasad termed it as a significant development that will allow the company to commence the clinical trials for Sputnik V in India. The volunteers were between 18 and 60 years old.
The Prime Minister is said to have told the meeting that the cooperation should be not restricted to the immediate neighbourhood; instead, India should reach out the entire world, with vaccines, medicines and IT platforms for vaccine delivery system.
While speaking on the COVID Vaccination & Consumers Rights, Prof Bejon Kumar Misra, International Consumer Policy Expert, Founder, JAGOGRAHAK.COM, Editor, The Aware Consumer, said, "Definitely, the vaccines will be a vital component in finally addressing the COVID-19 pandemic". However, the biggest challenge lies in its accessibility. For this, we need to prioritise the accessibility depending upon the vulnerability of the populace and take some strong action within the time limit. In comments to the media, scientists developing the vaccine said that it produced enough antibodies to protect the person who had it from the virus and that the immunity it creates could last for up to six months.
"Considering the overlaps in certain categories, we have estimated that a total of 550-600 million doses of the vaccine will be required initially for the priority population", an official said.
Elaborating on the status of the vaccine development, Samir Deb, Pharmaceutical Professional, Consultant Vaccine & Public Affairs Consultant, South East Asia, said, "Vaccine development is a burning issue across the world now".
The shots, which include the booster dose, are planned for the initial phase once a vaccine is approved for use.